Patient preferences for diabetic retinopathy health states

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 7, 2010, Pages 3387-3394

  Szabo, Shelagh M ^a   Beusterien, Kathleen M ^a   Pleil, Andreas M ^b   Wirostko, Barbara ^b   Potter, Michael J ^c   Tildesley, Hugh ^d   Gonder, John ^e   Barsdorf, Alexandra ^b   Levy, Adrian R ^a  

^a ICON PLC   (United Kingdom)

^b PFIZER INC   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Endocrine Research Society   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ARTICLE; CANADA; CONTRAST SENSITIVITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROSS-SECTIONAL STUDY; DEATH; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE COURSE; FEMALE; FUNCTIONAL STATUS; GENDER; HEALTH STATUS; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PATIENT PREFERENCE; PHYSICIAN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SAMPLE SIZE; STANDARDIZATION; VISION; VISUAL ACUITY; DAILY LIFE ACTIVITY; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT ATTITUDE; PHYSIOLOGY; SICKNESS IMPACT PROFILE; VISUAL DISORDER;

ACTIVITIES OF DAILY LIVING; CONTRAST SENSITIVITY; CROSS-SECTIONAL STUDIES; DIABETIC RETINOPATHY; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PATIENT PREFERENCE; QUALITY OF LIFE; SICKNESS IMPACT PROFILE; VISION DISORDERS; VISUAL ACUITY;

EID: 77955884387     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4194     Document Type: Article

References (44)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
2. Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet. 2007;369:750-756.
3. Bonow RO, Gheorghiade M. The diabetes epidemic: a national and global crisis. Am J Med. 2004;116(suppl 5A):2S-10S.
4. Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye. 2004;18:963-983.
5. US Centers for Disease Control. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States. Atlanta, GA: Centers for Disease Control and Prevention; 2005.
6. Evans J. Causes of Blindness and Partial Sight in England and Wales 1990-91. London: Office of Population Censuses and Surveys; 1995.
7. Happich M, Reitberger U, Breitscheidel L, Ulbig M, Watkins J. The economic burden of diabetic retinopathy in Germany in 2002. Graefes Arch Clin Exp Ophthalmol. 2008;246:151-159.
8. Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006;124:1754-1760.
9. Brown GC, Brown MM, Sharma S, Brown H, Gozum M, Denton P. Quality of life associated with diabetes mellitus in an adult population. J Diabetes Complications. 2000;14:18-24.
10. Brown DW, Balluz LS, Giles WH, et al. Diabetes mellitus and health-related quality of life among older adults: findings from the behavioral risk factor surveillance system (BRFSS). Diabetes Res Clin Pract. 2004;65:105-115.
11. Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev. 1999;15:205-218.
12. Wandell PE, Tovi J. The quality of life of elderly diabetic patients. J Diabetes Complications. 2000;14:25-30.
13. de Grauw WJ, van de Lisdonk EH, Behr RR, van Gerwen WH, van den Hoogen HJ, van Weel C. The impact of type 2 diabetes mellitus on daily functioning. Fam Pract. 1999;16:133-139.
14. Klein R, Moss SE, Klein BEK, Gutierrez P, Mangione CM. The NEI-VFQ-25 in people with long-term type 1 diabetes mellitus: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Ophthalmol. 2001;119:733-740.
15. Scanlon PH, Martin ML, Bailey C, Johnson E, Hykin P, Keightley S. Reported symptoms and quality-of-life impacts in patients having laser treatment for sight-threatening diabetic retinopathy. Diabet Med. 2006;23:60-66.
16. Lamoureux EL, Hassell JB, Keeffe JE. The impact of diabetic reti-nopathy on participation in daily living. Arch Ophthalmol. 2004; 122:84-88.
17. Sharma S, Oliver-Fernandez A, Liu W, Buchholz P, Walt J. The impact of diabetic retinopathy on health-related quality of life. Curr Opin Ophthalmol. 2005;16:155-159.
18. Hariprasad SM, Mieler WF, Grassi M, Green JL, Jager RD, Miller L. Vision-related quality of life in patients with diabetic macular oedema. Br J Ophthalmol. 2008;92:89-92.
19. Coyne KS, Margolis MK, Kennedy-Martin T, et al. The impact of diabetic retinopathy: perspectives from patient focus groups. Fam Pract. 2004;21:447-453.
20. de Boer MR, Moll AC, de Vet HC, Terwee CB, Volker-Dieben HJ, van Rens GH. Psychometric properties of vision-related quality of life questionnaires: a systematic review. Ophthalmic Physiol Opt. 2004;24:257-273.
21. Massof RW, Rubin GS. Visual function assessment questionnaires. Surv Ophthalmol. 2001;45:531-548.
22. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119:1050-1058.
23. Mangione CM, Lee PP, Pitts J, Gutierrez P, Berry S, Hays RD. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Arch Ophthalmol. 1998;116:1496-1504.
24. Lloyd A, Nafees B, Gavriel S, Rousculp MD, Bote KS, Ahmad A. Health utility values associated with diabetic retinopathy. Diabetic Med. 2008;25:618-624.
25. Brown GC. Vision and quality-of-life. Trans Am Ophthalmol Soc. 1999;97:473-511.
26. Brown GC, Brown MM, Sharma S, Beauchamp G, Hollands H. The reproducibility of ophthalmic utility values. Trans Am Ophthal-mol Soc. 2001;99:199-203.
27. Brown MM, Brown GC, Sharma S, Landy J, Bakal J. Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol. 2002;120:481-484.
28. Brown MM, Brown GC, Sharma S, Shah G. Utility values and diabetic retinopathy. Am J Ophthalmol. 1999;128:324-330.
29. Hollands H, Lam M, Pater J, et al. Reliability of the time trade-off technique of utility assessment in patients with retinal disease. Can J Ophthalmol. 2001;36:202-209.
30. Sharma S, Oliver-Fernandez A, Bakal J, Hollands H, Brown GC, Brown MM. Utilities associated with diabetic retinopathy: results from a Canadian sample. Br J Ophthalmol. 2003;87:259-261.
31. Sharma S, Brown GC, Brown MM, Hollands H, Robins R, Shah GK. Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients. Br J Ophthalmol. 2002;86: 493-496.
32. Tung TH, Chen SJ, Lee FL, Liu JH, Lin CH, Chou P. A community-based study for the utility values associated with diabetic retinop-athy among type 2 diabetics in Kinmen, Taiwan. Diabetes Res Clin Pract. 2005;68:265-273.
33. Shah VA, Gupta SK, Shah KV, Vinjamaram S, Chalam KV. TTO utility scores measure quality of life in patients with visual mor-bidity due to diabetic retinopathy or ARMD. Ophthalmic Epidemiol. 2004;11:43-51.
34. Lee BS, Kymes SM, Nease RF Jr, Sumner W, Siegfried CJ, Gordon MO. The impact of anchor point on utilities for 5 common ophthalmic diseases. Ophthalmology. 2008;115(5):898-903.e4.
35. Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A. Ranibi-zumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess. 2008;12:iii-201.
36. Bennet KJ, Torrance GW. Quality of Life and Pharmacoeconom-ics in Clinical Trials. 2nd ed; Philadelphia: Lippincott-Raven; 1996.
37. Persons with diabetes, by age and sex. Ottawa, ON, Canada: Statistics Canada; 2007.
38. Furlong W, Feeny D, Torrance GW, Barr R, Horsman J. Guide to design and development of health-state utility instrumentation. Hamilton, ON: Centre for Health Economics and Policy Analysis. McMaster University; 1990:1-141.
39. Sharma S, Brown GC, Brown MM, et al. Converting visual acuity to utilities. Can J Ophthalmol. 2000;35:267-272.
40. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ. 1986;5:1-30.
41. Woodcock A, Bradley C, Plowright R, ffytche T, Kennedy-Martin T, Hirsch A. The influence of diabetic retinopathy on quality of life: interviews to guide the design of a condition-specific, individualised questionnaire: the RetDQoL. Patient Educ Couns. 2004;53: 365-383.
42. Szlyk JP, Mahler CL, Seiple W, Vajaranant TS, Blair NP, Shahidi M. Relationship of retinal structural and clinical vision parameters to driving performance of diabetic retinopathy patients. J Rehabil Res Dev. 2004;41:347-358.
43. Krippendorff K. Content Analysis: An Introduction to Its Methodology. 2nd ed. Thousand Oaks, CA: Sage; 2004.
44. Brown GC, Sharma S, Brown MM, Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol. 2000;118: 47-51.